Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

This study has been completed.
Sponsor:
Information provided by:
Anthera Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00525954
First received: September 4, 2007
Last updated: January 3, 2008
Last verified: January 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: December 2007
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):